Skip to content

Effective Dose of Oliceridine for Inhibiting Hemodynamic Elevation Induced by Tracheal Intubation in children undergoing Adenotonsillectomy: An Up-and-Down Sequential Trial

Effective Dose of Oliceridine for Inhibiting Hemodynamic Elevation Induced by Tracheal Intubation in children undergoing Adenotonsillectomy: An Up-and-Down Sequential Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129287
Enrollment
Unknown
Registered
2026-08-03
Start date
2026-08-03
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enlarged tonsils / adenoids

Interventions

Younger Children Group (Group Y): 1–5 years old:The dose for the younger children group was set at Oliceridine 35 µg/kg , with a dose adjustment step of 2 µg/kg. If a child exhibited a positive cardi
if no positive response occurred, the dose was decreased by 2 µg/kg. The trial for each group was terminated after the seventh crossover point between positive and negative responses was reached.
Older Children Group (Group E): 6–14 years old:The dose for the older children group was set at Oliceridine 40 µg/kg, with a dose adjustment step of 2 µg/kg. If a child exhibited a positive cardiovas

Sponsors

Guangzhou Women and Children Medical Center Liuzhou Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Age 1–14 years old; 2. ASA classification I–II; 3. Children undergoing tonsil and/or adenoid removal under general anesthesia (tracheal intubation).

Exclusion criteria

Exclusion criteria: 1. Children who are allergic to the components of Oseli; 2. Children with acute upper respiratory tract infection symptoms before the operation; children with a history of bronchial asthma; 3. Children with existing or potential difficult airway conditions as assessed before the operation; 4. Children with related mental or neurological disorders and difficult to evaluate the analgesic effect; 5. Children with a history of chronic pain or long-term use of painkillers; 6. Children with other conditions that the researchers consider unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Oxalidine inhibits the ED50 and ED95 of the cardiovascular response to tracheal intubation;

Secondary

MeasureTime frame
Occurrence of cough after injection of oxalidine;Success rate of sedation;Hemodynamic changes before and after intubation;In the PACU, the PAED and FLACC scores;

Countries

China

Contacts

Public ContactLingyu Wang

Guangzhou Women and Children Medical Center Liuzhou Hospital

12881977@qq.com+86 772 220 5450

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026